This is highly valuable as integrating molecular profiling into future studies is essential to develop personalized treatment strategies and optimize patient selection for CDK4/6 inhibitor-based therapies in HER2-positive breast cancer. This evidence concerns the gene CDK4 and breast carcinoma.